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The 69 insertion and Q151M mutations are multi-nucleoside/
nucleotide resistance mutations (MNR). The prevalence
among 4078 antiretroviral therapy (ART)-experienced in-
dividuals was ,1.3%. Combined ART fully prevented MNR
in subtype B infections. Case-control studies were performed
to identify risk factors. Control subjects were patients
with >3 thymidine-analogue mutations. The 69 insertion
study (27 control subjects, 14 case patients) identified
didanosine exposure as a risk (odds ratio, 5.0 per year; P 5
.019), whereas the Q151M study (which included 44 control
subjects and 25 case patients) detected no associations.
Following detection, individuals with Q151M tended to have
lower suppression rates and higher mortality rates, relative to
control subjects. Additional studies are needed to verify these
findings in non-subtype B infections.
The introduction of highly-active antiretroviral therapy
(HAART) reduced morbidity and mortality of human immu-
nodeficiency virus (HIV) infected patients. However, drug re-
sistance continues to emerge in association with treatment
failure [1].
The 69 insertion and Q151M mutation are multi-nucleoside/
nucleotide resistance (MNR) mutations on the reverse tran-
scriptase that affect the activity of all approved nucleoside
reverse transcriptase inhibitors (NRTIs). Although 69 insertion
confers full resistance to all drugs, tenofovir retains some activity
when Q151M is present [2–4]. MNR mutations occur rarely in
European settings (prevalence, ,1% to 3.6%). The prevalence
in resource-limited countries has not been analyzed, but recent
reports indicate that it has increased [5–8]. The possible increase
in MNR HIV strains is of great concern because of the very
limited options for salvage treatment in resource-limited set-
tings and the general lack of understanding as to how to opti-
mally treat patients who have MNR infections [9].
We aimed to identify predictors for the emergence of the 69
insertion and Q151M mutation in the Swiss HIV Cohort Study
(SHCS) and studied outcomes of salvage regimens applied for
treatment of MNR HIV infections.
METHODS
Data and Patient Selection
Our analysis included data from the SHCS and the SHCS drug
resistance database up to February 2010 [10, 11]. The SHCS has
been approved by the ethical committees of all participating
institutions, and written informed consent has been obtained
from participants.
Prevalence of Acquired and Transmitted MNR Mutations
The prevalence of the 69 insertion and the Q151Mmutation was
analyzed among treatment-experienced (at least 30 days expo-
sure) and treatment-naive patients. Among treatment-naive
patients, possible transmission clusters were identified through
phylogenetic methods. These analyses were performed with
PHYLIP 3.6 (distributed by J. Felsenstein), using the F84 nu-
cleotide substitution model and the neighbor-joining tree al-
gorithm with 1000 bootstraps. To avoid interference of
treatment history, all major International AIDS Society–USA
drug resistance–associated amino acid positions were deleted
from the sequences prior to analysis [12].
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Case-control Study to Determine Predictors for MNR
We compared patients with MNR detected with patients
who carried viruses with >3 thymidine analogue mutations
(TAMs), either from the TAM 1 (M41L, L210W, T215Y) or
the TAM 2 pathway (D67N, K70R, T215F, K219K/E). The
rationale was to establish a control group consisting of highly
NRTI-experienced individuals with comparable charac-
teristics, except for the occurrence of 69 insertion or Q151M.
Separate matched case-control studies were performed for
each of the 2 MNR mutations. Control patients were matched
2:1 on the basis of the first antiretroviral therapy (ART) received
and the time between ART initiation and the detection of MNR
mutations (for case patients) or>3 TAMs (for control subjects).
Inclusion was restricted to individuals infected with HIV sub-
type B who started ART with single-class NRTI therapy.
Conditional logistic regression analyses were performed to
identify risk factors for the emergence of 69 insertion and
Q151M. Variables tested included the time spent on specific
NRTIs and adjustments for the following potential confounders:
sex, age, ethnicity, risk group, HIV-1 RNA level, and CD41 cell
count at time of detection of MNR mutations (for case patients)
or > 3 TAMs (for control subjects).
Factors Associated with Attaining Undetectable Viral Loads
After Detection of MNR Mutations
Virological outcomes after detection of MNR mutations were
analyzed for patients from the case-control studies with .1
follow-up HIV-1 RNA measurement. Characteristics and
treatments were compared between patients who ever achieved
2 consecutive undetectable HIV-1 RNA levels ,50 copies/mL
and patients who did not. Fisher’s exact test (categorical) and
Wilcoxon rank-sum test (continuous variables) were used.
Association of All-cause Mortality with Detection of MNR
Mutations
Cox proportional hazard models for matched case-control data
were estimated to analyze the time to all-cause mortality after
detection of MNR mutations (case patients) or >3 TAMs
(control subjects). Models were stratified by years of detection of
MNR mutations or >3 TAMs (1998, 1999–2003, after 2003).
The proportional hazard assumption was verified by analyzing
Schoenfeld residuals.
Statistical analyses were performed with Stata 11 SE (Stata-
Corp), all confidence intervals (CI) are 95% CIs, and the level of
significance was set at P 5 .05.
RESULTS
Prevalence of MNR Mutations in Treatment-experienced
Patients
The SHCS included 19 (0.5%) of 4078 and 34 (0.8%) of 4078
treatment-experienced patients who carried viruses with the 69
insertion and Q151M mutation, respectively. Most patients in
the 69 insertion and Q151M groups were treated with mono- or
dual-NRTI therapy (14 [73.7%] of 19 and 30 [88.2%] of 34,
respectively. MNR was never detected in patients who were
exclusively treated with HAART (2 NRTIs and 1 boosted pro-
tease inhibitor [PI]/nonnucleoside reverse transcriptase in-
hibitor [NNRTI]). The median duration of ART until detection
was 6.8 years for the 69 insertion group and 5.5 years for the
Q151M group. The median years of detection were 2000.5
(range: 1995–2007) and 2000 (range: 1995–2006), respectively.
Most individuals who carried viruses with MNR were infected
with subtype B viruses (18 [94.7%] of 19 and 29 [85.3%] of 34,
respectively). All additional analyses were restricted to this
subtype.
Evidence for MNR Transmission among Treatment-naive
Patients
We screened 5692 sequences from treatment-naive patients and
detected the 69 insertion 3 times (0.05%) and Q151M once
(0.02%). The phylogenetic analysis provided strong evidence of
forward transmission of the 69 insertion from 1 index patient to
2 patients (100% bootstrap support). All of these patients were
men who had sex with men and were from the same study
center. For Q151M, no transmission cluster was detected.
Predictors for the Emergence of MNR in Patients Infected with
HIV Subtype B
For the 69 insertion case-control study, matching criteria fitted
for 14 case patients (69 insertion) and 27 control subjects (>3
TAMs). Interestingly, years spent receiving didanosine were
significantly associated with the emergence of 69 insertion in
univariable (odds ratio [OR], 3.4; 95% CI, 1.2–9.6; P 5 .019)
and multivariable models (OR, 5.0; 95% CI, 1.3–19.3; P5 .019).
For the Q151M case-control study, 25 case patients and 44
control subjects (>3 TAMs) were matched, but conditional
logistic regressions failed to identify predictors for the
emergence of Q151M.
Virological Response to Salvage Treatment upon Emergence of
MNR
Virological outcomes for patients with .1 follow-up HIV-1
RNA measurement after MNR detection were analyzed. The
probability of ever achieving viral suppression was comparable
between the 69 insertion group (9 [69.2%] of 13; 95% CI,
38.6%–90.9%) and respective control subjects (15 [75.0%] of
20; 95% CI, 50.9%–91.3%). A large proportion of patients who
received previously unseen drug classes achieved viral suppres-
sion (87.5% compared to 40.0% of other patients; P5 .217). As
shown in table 1, all patients detected without major NNRTI or
PI mutations achieved viral suppression (patients 1, 4, and 8).
Five of 7 patients with either NNRTI or PI mutations achieved
viral suppression with the remaining active non-NRTI drug class
(patients 2, 5, 6, 7, and 11).
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Table 1. Characteristics of Patients who Achieved Viral Suppression and Characteristics of the First Successful Treatment following Detection of 69 Insertion or Q151M
Mutation,
patient
Year of
detection
Log10 HIV-1
RNA level at
detection,
copies/mL
CD41 cell
count at
detection,
cells/lL
CDC
stage
NRTI mutations
at detection
Majora NNRTI
mutations at
detection
Majora PI
mutations at
detection
Year of first
successful
treatment
Successful
treatment
Year of
loss of
follow-up
69 insertion
1 1995 4.4 50 C M41L, 69 insertion, L210W, T215Y 2003 TDF EFV ddI 2009
2 1995 4.2 118 B M41L, 69 insertion, K70R, M184V,
L210W, T215Y
Y188C 1999 NFV ZDV 3TC 2009
3 1997 5.9 32 C M41L, 69 insertion, L210W, T215Y M46L, V82A, L90M 2001b
4 1997 3.3 472 B M41L, 69 insertion, M184I, T215Y 1997 SQV RTV NVP D4T 2009
5 1997 4.3 315 C M41L, 69 insertion, T215Y I84V 2000 LPV IDV D4T 3TC 2009
6 1999 3.1 180 B M41L, 69 insertion, L210W, T215Y M46I, T74P, I84V,
L90M
2001 LPV EFV ddI 3TC 2009
7 1999 5.1 139 C M41L, 69 insertion, M184I, T215Y M46L, V82A, I84V 2002 EFV ddI ABC 2009
8 2001 4.2 415 B D67N, 69 insertion, K70R, K219Q 2004 RTV EFV ATV 3TC 2009
9 2002 4.8 542 B M41L, 69 insertion, T215Y Y181C M46I, G48V, I84V,
N88S, L90M
2009
10 2003 5.7 13 B M41L, 69 insertion, L74V, L210W,
T215Y
L100I, K103N M46I, L76V, V82F,
L90M
2003b
11 2004 4.8 198 B M41L, 69 insertion, M184V, L210W,
T215Y
M46I, I84V, L90M 2005 LPV EFV ZDV 3TC 2009
12 2004 5.1 367 C M41L, 69 insertion, L210W, T215Y M46L, V82A, L90M 2009
13 2007 2.9 358 B M41L, 69 insertion, M184V, L210W,
T215Y
K103N I54L, I84V, L90M 2008 TDF RAL ETV ABC 3TC 2009
Q151M
1 1995 5.4 160 A V75I, F77L, Y115F, F116Y, Q151M Q58E 2001b
2 1996 5.7 50 C F77L, F116Y, Q151M G48V, L90M 1997b
3 1996 4.2 100 C D67N, K70R, F77L, Q151M, T215F,
K219E
V108I 2000b
4 1996 3.5 162 B F116Y, Q151M, 1999 NFV D4T 3TC 2009
5 1996 4.4 133 C K65R, V75I, F77L, Y115F, F116Y,
Q151M, K219Q
2008 TDF RTV RAL MVC
ETV DRV ZDV 3TC
2009
6 1997 5.2 75 C M41L, A62V, V75I, F77L, F116Y,
Q151M, M184V
1998b
7 1997 2.6 464 A D67N, Q151M, K219Q 2001b
8 1997 3.6 61 C Q151M, M184V 2001b
9 1997 3.8 476 C D67N, F116Y, Q151M Q58E 1997 IDV D4T 3TC 2009
10 1998 5.1 15 C A62V, V75I, F77L, F116Y, Q151M,
M184V
K103N M46L, G48V,
V82A
2003b
11 1998 5.0 8 C M41L, D67N, F77L, F116Y,
Q151M, M184V, L210W, T215Y
M46I, V82A 2000b
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Table 1. (Continued)
Mutation,
patient
Year of
detection
Log10 HIV-1
RNA level at
detection,
copies/mL
CD41 cell
count at
detection,
cells/lL
CDC
stage
NRTI mutations
at detection
Majora NNRTI
mutations at
detection
Majora PI
mutations at
detection
Year of first
successful
treatment
Successful
treatment
Year of
loss of
follow-up
12 1998 3.9 412 B A62V, K65R, V75I, F77L, Y115F,
F116Y, Q151M, M184V
D30N 1999 SQV RTV EFV D4T ABC 2007b
13 1999 5.8 5 C D67N, Q151M V82A, I84V, L90M 2000b
14 1999 5.3 23 C D67N, K70R, F116Y, Q151M,
M184V, K219E
V82A, L90M 2007 RTV RAL ETV DRV 3TC 2009
15 2000 5.3 36 C M41L, D67N, K70R, Q151M,
M184V, T215F, K219E
K103N, V108I I54L, V82A, L90M 2002b
16 2000 4.9 481 B A62V, V75I, F77L, F116Y, Q151M 2002 LPV EFV ZDV ABC 3TC 2009
17 2001 2.5 259 C A62V, F116Y, Q151M, M184V, M46I 2002 EFV D4T 3TC 2003b
18 2001 4.7 229 A A62V, V75I, F77L, F116Y, Q151M I84V, L90M 2003 LPV EFV APV 3TC 2009
19 2001 5.0 253 C A62V, K65R, D67N, V75I, F77L,
Y115F, F116Y, Q151M,
M184V, K219E
D30N, M46I, I54M 2002 SQV NVP LPV 2009
20 2002 4.8 77 B K65R, K70R, V75I, F77L, Y115F,
F116Y, Q151M, K219E
K101E, Y181C,
G190A
M46I, V82A 2004 TDF RTV ETV ABC 2009
21 2003 3.9 191 C D67N, K70R, F116Y, Q151M,
M184V, K219Q
K103N M46I, Q58E, V82F,
L90M
2006b
22 2003 3.0 5 B A62V, D67N, K70R, V75I,
F77L, F116Y, Q151M,
M184V, K219E
K103N, V108I I50V, V82A, L90M 2004 TPV TDF T20 LPV
DDI ZDV APV 3TC
2009
23 2004 4.5 84 B D67N, K70R, Y115F, F116Y,
Q151M,
M184V, K219Q
Y181C, Y188L M46I, V82A 2006 TPV TDF RTV RAL
ZDV 3TC
2009
24 2004 3.9 461 B F116Y, Q151M, M46I, L90M 2007 RTV DRV 2008b
25 2006 4.8 773 A F116Y, Q151M K103N, Y188L 2006 TDF RTV FTC ATV 2009
NOTE. Viral suppression was defined as 2 consecutive viral loads ,50 copies/mL. 3TC, lamivudine; ABC, abacavir; APV, amprenavir; CDC, Centers for Disease Control and Prevention; D4T, stavudine; ddI, didanosine;
DRV, darunavir; EFV, efavirenz; ETV, etravirine; HIV-1, human immunodeficiency virus type 1; IDV, indinavir; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; RTV, ritanovir; SQV, saquinavir; T20, enfuvirtide; TDF, tenofovir; TPV, tipranavir; ZDV, zidovudine.
a Mutations printed in bold on the International AIDS Society-USA list [12].
b Year of death.
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Viral suppression rates between the Q151M group (14
[56.0%] of 25; 95% CI, 34.9%–75.6%) and the respective control
subjects (27 [73.0%] of 37; 95% CI, 55.9%–86.2%) were sim-
ilar. Generally, patients who achieved viral suppression had
a higher median CD41 cell count at detection (241 cells/lL vs 61
cells/lL; P 5 .030), a lower viral load (median log10 RNA level,
4.5 copies/mL vs 5.1 copies/mL; P 5 .089), a higher percentage
of a previously unseen drug class (88.9% vs 37.5%; P 5 .033),
and were detected later (median year, 1997 vs 2001; P 5 .027).
As illustrated in Table 1, most patients with Q151M detected
before the introduction of HAART never achieved viral sup-
pression (patients 1–3 and 6–8). Four of 11 patients detected
in the HAART era prior to the approval of enfuvirtide (T20)
(1998–2002) never had a successful treatment (patients 10, 11,
13, and 15). All of these patients had low CD41 cell counts (,50
cells/lL) and extensive PI and/or NNRTI mutations. Most of the
other patients had PI mutations but achieved viral suppression
with a regimen containing NNRTIs (patients 12, 14, and 16–20).
Survival after Detection of MNR
The crude incidence of mortality after detection of the 69 in-
sertion was 1.9 deaths (95% CI, 0.2–6.9) per 100 person-years of
follow-up, compared with 6.3 deaths (95% CI, 2.9–12.0) per 100
person-years of follow-up among control subjects (>3 TAMs)
[Figure 1]. Of the 2 deaths noted in the 69 insertion group, 1
death was HIV-related, and the cause of the other death was
unknown. The risk of mortality was not significantly different
between patients with the 69 insertion and those with>3 TAMs
(univariable hazard ratio [HR], 0.3 [95%CI, 0.1–1.6]; P5 .178).
The small number of events did not allow stratified or multi-
variable models.
Patients with Q151M detected tended to have a higher crude
incidence of 9.8 deaths per 100 person-years (95% CI, 5.3–16.4),
compared with 5.8 death per 100 person-years (95%CI, 3.3–9.4)
in control subjects (with >3 TAMs) [Figure 1]. HIV infection
was the cause of death for 6 (42.9%) of 14 patients from the
Q151M group and 7 (43.8%) of 16 control subjects. Additional
causes of death reported in the Q151M group were neoplasm
(14.3%), cardio-vascular diseases (14.3%), chronic hepatitis C
(7.1%), suicide (7.1%), or unknown (14.3%). The detection of
Q151M was associated with increased mortality but was of
marginal statistical significance in the univariable (HR, 2.7 [95%
CI, 0.9–8.0]; P 5 .075) and multivariable model, adjusted for
sex, ethnicity, risk group, CD41 cell count, and age (HR, 7.5
[95% CI, 0.9–64.6]; P 5 .068).
Sensitivity analyses including only those deaths associated
with HIV infection (univariable HR, 2.6 [95% CI, 0.6–10.4];
P5 .189) or by additionally matching case patients and control
subjects by CD41 cell count at time of detection of Q151M
or >3 TAMs showed similar results (univariable HR, 3.2 [95%
CI, 1.0–10.9]; P5 .058; and multivariable HR, 6.2 [95% CI, 0.7–
56.0]; P 5 .105).
DISCUSSION
Because the prevalence of MNR is increasing in resource-limited
countries, and because 69 insertion and Q151M affect the ac-
tivity of an entire drug class, it is of great importance to identify
risk factors and to optimize treatment strategies.
Our study currently represents the largest longitudinal dataset
with full treatment history available. We found high evidence of
forward transmission of 69 insertions. This finding is of rele-
vance, because the presence of 69 insertion results in a sub-
stantial reduction of treatment options, which can be devastating
in settings with limited access to potent salvage therapies.
Moreover, our study identified a significant association of ddI
exposure with the emergence of the 69 insertion [13]. No spe-
cific NRTI was associated with the emergence of Q151M.
Our study did not confirm a previously reported negative as-
sociation of lamivudine with Q151M [2, 14], nor was d4T ex-
posure correlated with an increased risk for Q151M (data not
shown).
Figure 1. Kaplan-Meier curves showing survival after detection of 69
insertion (a) or Q151M (b). Patients detected with>3 thymidine analogue
mutations (TAMs) were matched (2:1) for comparison. Log-rank test was
stratified for matched pairs.
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Of note, MNRmutations were never detected in patients who
were exclusively treated with HAART. This is in contrast to the
high prevalence ofMNRmutations observed in resource-limited
settings [7, 8]. Free access to potent antiretroviral drugs in
Switzerland and close monitoring are the most likely ex-
planations for this difference.
Moreover, this study widened the very limited knowledge
for treatment strategies of patients detected with MNR. These
patients can be successfully treated if potent drugs, such as
boosted PI, raltegravir, or T20 are available. The descriptive
analysis of therapy success further suggests that extensive re-
sistance to NNRTIs and PIs, as well as a low CD41 cell count at
the time of detection of MNR mutations, were prognostically
unfavorable [15].
Patients with viruses possessing Q151M tended to have an
increased mortality risk, compared with patients with >3
TAMs. Although this finding was robust throughout several
sensitivity analyses, conclusions regarding causality between
Q151M and death should be drawn with care.
This study has some limitations. Even though our sample is
the largest study to date to address MNR, it is still limited in
power [11]. Our study was restricted to subtype B–infected
individuals, and results may therefore not be readily transferable
to other subtypes.
Taken together, our data indicate that modern anti-
retroviral therapies in combination with adequate viral
monitoring are able to prevent the emergence of MNR mu-
tations in developed settings. In Switzerland, detected MNR
mutations are mainly a relic of the mono- or dual-NRTI
therapy era, although 2 cases of transmitted MNR were
observed. This analysis further demonstrates that salvage
treatment can be successful even when MNR mutations are
present if at least 1 previously unused drug class is available.
Today, the development of MNR seems to be becoming an
emerging problem in resource-limited settings, where most
patients are infected with non–subtype B strains. Thus,
additional studies are needed to investigate whether our
findings are also true for non–subtype B infections.
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